Skip to Content

CHP research capabilities

Neurocognitive testing

  • Computerised Mental Performance Assessment (COMPASS) battery developed specifically to capture the effects of nutritional interventions on cognitive performance
  • The Cognitive Drug Research (CDR) battery used in over 1000 clinical trials including those assessing effects of food ingredients and supplements
  • Swinburne University Computerised Cognitive Assessment Battery (SUCCAB), specifically designed to be sensitive to the cognitive effects of ageing and interventions which reverse cognitive ageing
  • Other tailored computerised and paper-and-pencil assessments

Stress and mood assessment

  • Including standardized self-report measures, laboratory stressors and biomarkers (e.g. Autonomic Nervous System activity, cortisol)

Psychiatric assessment

  • Depression, anxiety disorders, ADHD etc. and their response to specific nutraceutical and pharmaceutical interventions.

Brain imaging techniques

(currently available and from Jan 2011 co-housed in dedicated research facilities)

  • Functional Magnetic Resonance Imaging (fMRI)
  • Magnetoencephalography (MEG)
  • Electroencephalography (EEG)
  • Transcranial Magnetic Stimulation (TMS)
  • Near Infrared Spectroscopy (NIRS)

Other techniques which assess cognition-relevant biomarkers include

  • Cardiovascular function
    • Doppler ultrasound
    • Flow-mediated dilatation(FMD)
    • Arterial compliance
  • Inflammation
  • Oxidative stress
  • other specific biomarkers

Clinical Trials facilities at Sarawak campus, Malaysia

The CHP conducts research with colleagues at Swinburne's Sarawak campus in Malaysia. Importantly this linkage gives us the capacity to conduct single and dual-centre clinical trials examining the effects of nutraceutical and other interventions on neurocognitive performance in different populations.

The following links provide examples of this work.

 
[an error occurred while processing this directive]